Table 2.
Therapeutics comparisons between patients groups.
| Parameter | Allopurinol group N = 97 |
Control group N = 97 |
P value |
|---|---|---|---|
| Diabetes mellitus medications | |||
| Insulin | 25 (25.77%) | 27 (27.94%) | 0.746 |
| Sulphonylureas | 14 (14.43%) | 20 (20.62%) | 0.257 |
| Metformin | 89 (91.75%) | 94 (96.91%) | 0.121 |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | 30 (30.93%) | 35 (36.08%) | 0.447 |
| Sodium Glucose cotransporters (SGLTs) inhibitors | 9 (9.28%) | 8 (8.25%) | 0.800 |
| Glucagon-like peptide-1 (GLP-1) agonists | 6 (6.19%) | 1 (1.03%) | 0.054 |
| Other medications | |||
| Angiotensin Converting Enzyme Inhibitors (ACEI)/ Angiotensin Receptor Blockers (ARB) | 16 (16.49%)/51 (52.58%) | 24 (24.74%)/35 (36.08%) | 0.156/0.021 |
| Beta-blockers/Calcium channel blockers | 48 (49.48%)/48 (49.48%) | 27 (27.84%)/27 (27.84%) | 0.002/0.002 |
| Hydrochlorothiazide/Furosemide | 26 (26.80%)/22 (22.68%) | 15 (15.46%)/10 (10.31%) | 0.053/0.020 |
| Spironolactone | 8 (8.25%) | 3 (3.09%) | 0.121 |
| Aspirin/Clopidogrel | 44 (45.36%)/8 (8.25%) | 58 (59.79%)/10 (10.31%) | 0.044/0.621 |
| Statins/Fenofibrate | 78 (80.41%)/10 (10.31%) | 77 (79.38%)/7 (7.22%) | 0.858/0.446 |
| Nitrates | 8 (8.25%) | 7 (7.22%) | 0.788 |
| Digoxin | 1 (1.03%) | 1 (1.03%) | 1.000 |
| Warfarin | 1 (1.03%) | 2 (2.06%) | 0.561 |
Chi-squared test for association was used for the comparisons.